Skip to main content

Table 3 Clinical and microbiological outcomes according to the antibiotic groups

From: Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

 

Piperacillin/tazobactam

(N = 33)

Cefepime

(N = 6)

Ertapenem

(N = 33)

p-value

Clinical success, n (%)

31 (93.9)

2 (33.3)

32 (97.0)

<0.001

Microbiological success, n (%)

32 (97.0)

2 (33.3)

32 (97.0)

<0.001

Clinical and microbiological success, n (%)

31 (93.9)

2 (33.3)

32 (97.0)

<0.001

28-days mortality, n (%)

2 (6.1)

2 (33.3)

2 (6.1)

0.108

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us